Sign in
← All bills
HB 642Just filedInsurance & financial services

Limits prior authorization to once a year for neurodegenerative disease drugs

The short version · AI summary

Health plans that cover prescription drugs could not require an enrollee to get more than one prior authorization (advance approval) per year for a drug prescribed to treat a neurodegenerative disease. This adds such diseases to the existing once-a-year limit for autoimmune diseases, hemophilia and Von Willebrand disease. A plan may still require new approval when an enrollee is prescribed a new drug for a neurodegenerative disease. It applies to plans delivered, issued or renewed on or after January 1, 2028. The act takes effect September 1, 2027.

What it means for you

If you or a family member takes a drug for a neurodegenerative disease, your plan could ask for approval of that drug only once a year. A new drug could still need new approval.

One email when it moves, at most one a day. Unsubscribe in one click from any email.

Bill Facts

HB 642 · Filed Nov 9, 2026
Who it affects
  • People with neurodegenerative diseases who have health plan drug coverage
  • Health benefit plan issuers (insurers)
  • Doctors who prescribe drugs for these diseases
What changes
  • Health plans could require only one prior authorization (advance approval) per year for a drug prescribed for a neurodegenerative disease.
  • A plan could still require approval when a patient is prescribed a new drug for a neurodegenerative disease.
When it starts
September 1, 2027, if it becomes law. It applies to health plans delivered, issued or renewed on or after January…
What it changes
1 tag, with the bill’s own words

What it changes

Each tag says one thing the bill changes, with the bill’s own words. A major tag reaches many people, a lot of money or a core right.

Adds rules for business

Major

Extends the limit of one prior authorization per year to drugs prescribed for neurodegenerative diseases, restricting how health plan issuers manage prescription drug benefits.

Quoted from the bill text
a neurodegenerative disease,+] hemophilia, or Von Willebrand disease.

Reviewed by AI on Nov 12, 2026 · Reviewed text version I

How reviews work
  • The plain-words summaries and notes are written by AI, not by a person.
  • Every quote is checked against the bill, letter for letter, before it is shown. A note whose words cannot be found in the bill is dropped.
  • Editors may correct a summary, an area of life or a note.

Where it is now

A bill is filed first. Then it goes to a committee, a small group of lawmakers who study it. After that, the House and the Senate each vote.

  1. Step 1
    Filed
    A lawmaker turned the bill in.
    You are here.
  2. Step 2
    A committee studies it
    A small group of lawmakers studies the bill, holds a hearing and votes.
  3. Step 3
    One side votes
    The House or the Senate votes on the bill.
  4. Step 4
    The other side votes
    The other part votes too.
  5. Step 5
    The governor decides
    The governor signs the bill into law or vetoes it, which means says no.

The bill, word for word

This is the bill as filed. A bill that changes a law shows what it adds and what it removes.

The record

Bill text
Session
90th Legislature, regular session
Author
Venton Jones
Subjects
Health--Other Diseases & Medical Conditions, Insurance--Health & Accident, MEDICINE & PRESCRIPTION DRUGS
Documents
None yet
Witnesses
None yet

What happened so far

Every official action on this bill, newest first.

  1. Nov 9, 2026
    Filed
HB 642: Limits prior authorization to once a year for neurodegenerative disease drugs | 51capitol